RP
Regeneron Pharmaceuticals (Tarrytown, NY). 2024 revenue ~$14B. Dupixent (dupilumab, mit Sanofi). Eylea (aflibercept). Libtayo (cemiplimab). VelocImmune mouse platform. 2024 FDA approval: itepékimab.
RP
Regeneron Pharmaceuticals
@regeneron
Joined July 2026
4 Following2 Followers